Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study

American Journal of Transplantation

Volumn 13, Issue 2, 2013, Pages 474-484

  Shihab, F S ^a   Lee, S T ^a   Smith, L D ^a   Woodle, E S ^b   Pirsch, J D ^c   Gaber, A O ^d   Henning, A K ^e   Reisfield, R ^f   Fitzsimmons, W ^f   Holman, J ^f  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e EMMES CORPORATION   (United States)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Corticosteroid withdrawal; kidney transplantation; mycophenolate mofetil; pharmacokinetics; tacrolimus

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CREATININE; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; POTASSIUM; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADRENAL CORTEX HORMONES; ADULT; AFRICAN AMERICANS; BODY MASS INDEX; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; TACROLIMUS;

EID: 84873095890     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04327.x     Document Type: Article

References (28)

1. Opelz G,. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443-446.
2. Opelz G, Dohler B, Laux G,. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005; 5: 730-728.
3. Pascual J, Galeano C, Royuela A, Zamora J,. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010; 90: 343-349.
4. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P,. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
5. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J,. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307-316.
6. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplant, 2011: p. 24.
7. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T,. Human p-glycoprotein transports cyclosporine A and FK506. J Bio Chem 1993; 268: 6077-6080.
8. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R,. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett 1999; 442: 208-214.
9. Hasselink DA, Nguyen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recvipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003; 56: 327-330.
10. Van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP,. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int, 2003; 16: 721-725.
11. Smith LD, Allard JA, Corbett J, Nelson E, Shihab F,. Tacrolimus nephrotoxicity as a result of steroid withdrawal in renal transplant recipients [abstract]. Am J Transplant, 2005, 5 (Suppl 11), 159.
12. Undre NA, Schafer A, and the European Tacrolimus Multicentre Renal Study Group. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplant. Transplant Proc 1998; 30: 1261-1263.
13. Anglicheau D, Flamant D, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409-2414.
14. Pelletier RP, Akin EB, Bumgardner GL, Rajab A, Elkhammas EA, Henry ML,. Mycophenolate mofetil dose reduction influences clinical outcome following kidney transplantation [abstract]. Am J Transplant 2003, 3 (Suppl 5), 577.
15. Knoll GA, MacDonald I, Khan A, van Walraven C,. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol, 2003; 14: 2381-2386.
16. Pascual J, Ocana J, Marcen R, et al. Mycophenolate mofetil tolerability and dose changes in tacrolimus-treated renal allograft recipients. Transplant Proc, 2006; 38: 2398-2399.
17. Vadivel N, Garg A, Holt DW, Chang RW, MacPhee IA,. Tacrolimus dose in black renal transplant recipients. Transplantation, 2007; 83: 997-999.
18. Andrews PA, Sen M, Chang RW,. Racial variation in dosage requirements of tacrolimus. Lancet, 1996; 348: 1446.
19. Neylan JF,. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation, 1998; 65: 515-523.
20. Mancinelli LM, Frassetto L, et al. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther, 2001; 69: 24-31.
21. Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: Polymorhpisms associated with expression of cytochrome p450 3A5 and P-glycoprotein correlate with dose requirement. Transplantation, 2000; 74: 1486-1489.
22. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet, 2010; 49: 141-175.
23. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet, 2010; 49: 207-221.
24. Sifontis NM, Benedetti E, Vasquez EM,. Clinical significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc, 2002; 34: 1730-1732.
25. Nankivell BJ, Borrows RJ, Fung C, O'Connell PJ, Allen R, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med, 2003; 349: 2326-2333.
26. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after kidney transplantation. Clin Transplant, 2003; 17: 200-205.
27. Knoll GA, MacDonald I, Khan A, Van Walraven C,. Mycophenolate mofetil dose reduction and the risk of acute rejection after kidney transplantation. J Am Soc Nephrol, 2003; 14: 2381-2386.
28. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA,. Long-term outcome of gastrointestinal complications in kidney transplant patients treated with mycophenolate mofetil. Transpl Int, 2004; 17: 609-616.